Compare PETS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETS | MIST |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 136.9M |
| IPO Year | 2003 | 2019 |
| Metric | PETS | MIST |
|---|---|---|
| Price | $1.80 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 106.4K | ★ 1.4M |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.00 |
| 52 Week High | $4.10 | $3.06 |
| Indicator | PETS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 40.23 |
| Support Level | $1.70 | $1.01 |
| Resistance Level | $1.87 | $1.42 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.82 | 12.12 |
PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.